Industry news that matters to you.  Learn more

Archives for October 2014

Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip

Antigen Discovery Inc. (ADi), a privately held company in Irvine, California, announced the receipt of a National Institutes of Health (NIH) Phase I Small Business Innovation Research award (SBIR) from the National Institute of Dental and Craniofacial Research (NIDCR). The one-year $225,000 award will fund the development of a Pan-HIV Protein Microarray Chip, which will contain every protein in all of the HIV-1 and HIV-2 subtypes and aid in the development of safe and effective vaccines and therapies to prevent HIV infection.

bioTheranostics Awarded Medicare Coverage for Breast Cancer Index Molecular Test

bioTheranostics, Inc., a leader in molecular diagnostics for cancer, recently announced that its Breast Cancer Index test has been awarded Medicare coverage. The Centers for Medicare and Medicaid Services posted a positive coverage and reimbursement policy after evaluation by Palmetto GBA, the Medicare administrator responsible for the MolDx molecular diagnostic technology assessment program.

SomaLogic Announces Agreement to Place SOMAscan Proteomics Assay in NIH Center for Human Immunology, Autoimmunity and Inflammation

SomaLogic, Inc., recently announced that the National Institutes of Health (NIH) Center for Human Immunology, Autoimmunity and Inflammation (CHI) will use the SOMAscan™ proteomics assay for research with collaborators across the NIH. It is expected that the SOMAscan assay will be installed and fully functional at CHI by the beginning of 2015, under the leadership of CHI Director Neal S. Young, M.D.

David and Barbara Roux Provide Historic $10 Million Gift to Advance Genomic Medicine Research at The Jackson Laboratory

The Jackson Laboratory (JAX) has announced that technology investor David Roux and his wife Barbara have gifted $10 million to support research and find cures for genetically based diseases. The center will be based at the Laboratory’s locations in both Maine and Connecticut.

Abcodia Offers Access to its Unique Longitudinal Serum Biobank to Advance Biomarker R&D for Haematological Cancers

Abcodia recently announced an initiative to license access to serum samples from its unique longitudinal serum biobank for use in discovery and validation of biomarkers for haematological cancers. This unparalleled resource, believed to be the largest longitudinal collection of its kind, can substantially reduce the time to market and cost of R&D.